Antidepressant use in multiple sclerosis: epidemiologic study of a large community sample

Abstract

Depressive symptoms and disorders among individuals with multiple sclerosis (MS) are more common when compared to other chronic illnesses and the general population, but relatively little is known about the use of antidepressant medication in this population. In this cross-sectional study of 542 community-dwelling adults with MS, we examined the prevalence of antidepressant use and employed multivariate logistic regression modeling to identify factors significantly associated with antidepressant use. Thirty-five percent of the sample reported currently using at least one antidepressant medication. Gender, marital status, insurance status, fatigue, and use of disease modifying therapies were all significantly associated with antidepressant use. Just over half of the sample endorsed a clinically significant level of depressive symptoms, and the majority of this group was not currently taking an antidepressant. Conversely, 41% of those with depressive symptoms reported taking at least one antidepressant medication. More research is needed to better understand why people with MS and depressive symptoms use or do not use antidepressant medications and to further explore the possibility of an under-treatment of depressive disorder in this population. Rigorous studies testing the feasibility, acceptability, and efficacy of currently available therapies for depression in the MS population should also be conducted. Multiple Sclerosis 2007; 13: 1046—1053. http://msj.sagepub.com

Keywords

antidepressant drugs depression multiple sclerosis predictors of antidepressant use

Get full access to this article

View all access options for this article.

References

Minden SL , Schiffer RB Affective disorders in multiple sclerosis. Review and recommendations for clinical research. Arch Neurol 1990; 47: 98—104.

Rao SM , Huber SJ , Bornstein RA Emotional changes with multiple sclerosis and Parkinson's disease. J Consult Clin Psychol 1992; 60: 369—78.

Schiffer RB , Babigian HM Behavioral disorders in multiple sclerosis, temporal lobe epilepsy, and amyotrophic lateral sclerosis. An epidemiologic study. Arch Neurol 1984; 41: 1067—69.

Schubert DS , Foliart RH Increased depression in multiple sclerosis patients. A meta-analysis. Psychosomatics 1993; 34: 124—30.

Wells KB , Golding JM , Burnam MA Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry 1988; 145: 976—81.

Joffe RT , Lippert GP , Gray TA , Sawa G. , Horvath Z. Mood disorder and multiple sclerosis. Arch Neurol 1987; 44: 376—78.

Minden SL , Orav J. , Reich P. Depression in multiple sclerosis. Gen Hosp Psychiatry 1987; 9: 426—34.

Patten SB , Metz LM , Reimer MA Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler 2000; 6: 115—20.

Sadovnick AD , Remick RA , Allen J. , Swartz E. , Yee IM , Eisen K. et al. Depression and multiple sclerosis. Neurology 1996; 46: 628—32.

10.

Chwastiak L. , Ehde DM , Gibbons LE , Sullivan M. , Bowen JD , Kraft GH Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry 2002; 159: 1862—68.

11.

Dalos NP , Rabins PV , Brooks BR , O'Donnell P. Disease activity and emotional state in multiple sclerosis. Ann Neurol 1983; 13: 573—77.

12.

Whitlock FA , Siskind MM Depression as a major symptom of multiple sclerosis. J Neurol Neurosurg Psychiatry 1980 ; 43: 861—65.

13.

Ehde DM , Bombardier CH Depression in persons with multiple sclerosis. Phys Med Rehabil Clin N Am 2005; 16: 437—48, ix.

14.

Mohr DC , Goodkin DE Treatment of depression in multiple sclerosis: review and meta-analysis. Clin Psychol Sci Pract 1999; 6: 1—9.

15.

Schiffer RB , Wineman NM Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry 1990; 147: 1493—97.

16.

Scott TF , Nussbaum P. , McConnell H. , Brill P. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurol Res 1995; 17: 421—22.

17.

Mohr DC , Goodkin DE , Islar J. , Hauser SL , Genain CP Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch Neurol 2001; 58: 1081—86.

18.

McIvor GP , Riklan M. , Reznikoff M. Depression in multiple sclerosis as a function of length and severity of illness, age, remissions, and perceived social support. J Clin Psychol 1984; 40: 1028—33.

19.

Ron MA , Logsdail SJ Psychiatric morbidity in multiple sclerosis: a clinical and MRI study. Psychol Med 1989; 19: 887—95.

20.

Logsdail SJ , Callanan MM , Ron MA Psychiatric morbidity in patients with clinically isolated lesions of the type seen in multiple sclerosis: a clinical and MRI study. Psychol Med 1988; 18: 355—64.

21.

Bakshi R. , Shaikh ZA , Miletich RS , Czarnecki D. , Dmochowski J. , Henschel K. et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 2000 ; 6: 181—85.

22.

Voss WD , Arnett PA , Higginson CI , Randolph JJ , Campos MD , Dyck DG Contributing factors to depressed mood in Multiple Sclerosis. Arch Clin Neuropsychol 2002; 17: 103—15.

23.

Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology 2002; 59: 674—78.

24.

The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 2005; 11: 328—37.

25.

Haigh R. , Tennant A. , Biering-Sorensen F. , Grimby G. , Marincek C. , Phillips S. et al. The use of outcome measures in physical medicine and rehabilitation within Europe. J Rehabil Med 2001; 33: 273—78.

26.

Nayak S. , Matheis RJ , Schoenberger NE , Shiflett SC Use of unconventional therapies by individuals with multiple sclerosis. Clin Rehabil 2003; 17: 181—91.

27.

Sastre-Garriga J. , Munteis E. , Rio J. , Pericot I. , Tintore M. , Montalban X. Unconventional therapy in multiple sclerosis . Mult Scler 2003; 9: 320—22.

28.

Lublin FD , Reingold SC Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907—11.

29.

DiGiacomo A. , Hinton K. , Johnson K. , Amtmann D. , Bowen J. Evaluation of self-administered MS disease course questionnaire. International Journal of MS Care 2006; 8: 51. Ref Type: Abstract.

30.

The Consortium of Multiple Sclerosis Centers Health Services Research Subcommittee. Multiple sclerosis quality of life inventory: a user's manual. National Multiple Sclerosis Society, 1997.

31.

Radloff LS The CES-D Scale: a self-report depression scale for research in the general population. J Applied Psychol Measurement 1977; 1: 385—401.

32.

Weissman MM , Sholomskas D. , Pottenger M. , Prusoff BA , Locke BZ Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 1977; 106: 203—14.

33.

Myers JK , Weissman MM Use of a self-report symptom scale to detect depression in a community sample . Am J Psychiatry 1980; 137: 1081—84.

34.

Unutzer J. , Patrick DL , Marmon T. , Simon GE , Katon WJ Depressive symptoms and mortality in a prospective study of 2,558 older adults . Am J Geriatr Psychiatry 2002; 10: 521—30.

35.

Sherbourne CD , Stewart AL The MOS social support survey. Soc Sci Med 1991; 32: 705—14.

36.

Ware JE Measuring patients' views: the optimum outcome measure. Br Med J 1993; 306: 1429—30.

37.

Goldstein MS , Siegel JM , Boyer R. Predicting changes in perceived health status . Am J Public Health 1984; 74: 611—14.

38.

Wilson IB , Kaplan S.

Clinical practice and patients' health status: how are the two related?

Med Care 1995; 33(4 Suppl): AS209—14.

39.

Bowen J. , Gibbons L. , Gianas A. , Kraft GH Self-administered Expanded Disability Status Scale with functional system scores correlates well with a physician-administered test. Mult Scler 2001; 7: 201—206.

40.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444—52.

41.

STATA 8.0 [computer program]. StataCorp LP; 2004.

42.

Kessler RC , McGonagle KA , Swartz M. , Blazer DG , Nelson CB Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord 1993; 29: 85—96.

43.

Mamdani M. , Herrmann N. , Austin P. Prevalence of antidepressant use among older people: population-based observations . J Am Geriatr Soc 1999; 47: 1350—53.

44.

The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277—85.

45.

Neilley LK , Goodin DS , Goodkin DE , Hauser SL Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology 1996; 46: 552—54.

46.

Borras C. , Rio J. , Porcel J. , Barrios M. , Tintore M. , Montalban X. Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b. Neurology 1999; 52: 1636—39.

47.

Feinstein A. , O'Connor P. , Feinstein K. Multiple sclerosis, interferon beta-1b and depression A prospective investigation. J Neurol 2002; 249: 815—20.

48.

Walther EU , Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management . Neurology 1999; 53: 1622—27.

49.

Rimes KA , Chalder T. Treatments for chronic fatigue syndrome. Occup Med (Lond) 2005; 55: 32—39.

50.

Hernan MA , Olek MJ , Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 2001; 154: 69—74.

51.

Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harv Rev Psychiatry 2000; 7: 257—77.

52.

Ehde DM , Osborne TL , Jensen MP Chronic pain in persons with multiple sclerosis. Phys Med Rehabil Clin N Am 2005; 16: 503—12.

53.

Pederson KJ , Roerig JL , Mitchell JE Towards the pharmacotherapy of eating disorders . Expert Opin Pharmacother 2003; 4: 1659—78.

54.

Wilson S. , Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005; 65: 927—47.

55.

Torrens M. , Fonseca F. , Mateu G. , Farre M. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend 2005; 78: 1—22.

56.

Olden KW The use of antidepressants in functional gastrointestinal disorders: new uses for old drugs. CNS Spectr 2005; 10: 891—96.

57.

Depression Guidelines Panel. Depression in primary care: treatment of major depression. U.S. Department of Health and Human Services, AHRO (formerly AHCPR), U.S. Public Health Services; 1993. Report No. 93-0551.

58.

Schulberg HC , Katon W. , Simon GE , Rush AJ Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry 1998; 55: 1121—27.

59.

Schulberg HC , Katon WJ , Simon GE , Rush AJ Best clinical practice: guidelines for managing major depression in primary medical care. J Clin Psychiatry 1999; 60(Suppl 7): 19—26.